SecBot SecBot
8-K ·Filed Apr 13, 2026

SEPN

Septerna, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago SEC0001193125-26-152045
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor for Phase 1 data from SEP-479 trial in late 2026/early 2027, which could be a catalyst for the stock. The company's cash runway into 2029 provides runway for clinical development, but no immediate financial impact from this announcement.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$23.34
T+0 close · Apr 13, 2026 · via day close
Latest settled
+55.96%
T+60 · $36.40
Vs SPY
+47.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $23.34entry
  2. T+1 · 7mo ago +3.38%α +2.17% · $24.13
  3. T+5 · 7mo ago +15.08%α +11.79% · $26.86
  4. T+20 · 6mo ago +0.99%α −6.74% · $23.57
  5. T+60 · 4mo ago +55.96%α +47.03% · $36.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Septerna announced the initiation of Phase 1 clinical trials for its oral PTH1R agonist SEP-479 for hypoparathyroidism, with data expected in late 2026 or early 2027. The company also provided updates on its other clinical programs including SEP-631 and its collaboration with Novo Nordisk, while highlighting its cash runway into 2029.

Key Facts

  • Company initiated Phase 1 clinical trial for SEP-479, an oral PTH1R agonist for hypoparathyroidism
  • Phase 1 trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) study in healthy volunteers
  • Data from the trial is anticipated in late 2026 or early 2027
  • SEP-631 Phase 1 study demonstrated robust pharmacodynamics with QD dosing
  • Company plans to initiate Phase 2b trial in chronic spontaneous urticaria in 2H 2026
  • Cash runway expected to support operating plans at least into 2029
  • Company has a $195M upfront payment from Novo Nordisk collaboration

Financial Impact

No immediate financial impact disclosed, but advancement of clinical programs could impact future revenue potential

cash runwayR&D expensesfuture revenue potential

Risk Factors

  • Clinical trial results may not meet expectations
  • Development timelines may be delayed
  • Competition in hypoparathyroidism and urticaria markets

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-152045
Document: d57504d8k.htm0001193125-26-152045
Document: d57504dex991.htm0001193125-26-152045
Document: 0001193125-26-152045-index-headers.html0001193125-26-152045
Document: 0001193125-26-152045-index.html0001193125-26-152045
Document: 0001193125-26-152045.txt0001193125-26-152045

US Market Status

Market Closed · Opens Wed (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026